Cannabis giant Tilray Brands, Inc. (NASDAQ:TLRY) announced Wednesday it has obtained second approval for a new medical marijuana extract in Portugal. The medical cannabis extract that got this approval is Tilray Oral Solution THC10:CBD10.
This milestone follows up on the successful approval of Tilray Medical's whole flower THC 18, and approval for the first cannabis extract in Portugal earlier this year. Tilray has been working on its European presence extensively this year. This week the company confirmed its German cannabis cultivation facility, Aphria RX GmbH, has obtained the first new cannabis cultivation license issued under MedCanG, Germany's new Cannabis Act.
"We are proud to have received approval for our Tilray Solução Oral THC10:CBD10 product and expanding our medical cannabis offerings for patients in Portugal," said Denise Faltischek, chief strategy officer and head of international at Tilray Brands, Inc. "This is a significant step towards meeting the critical needs of patient care and providing high-quality cannabis products and therapeutic options to those with specific medical conditions. The approval of this oral cannabis solution in Portugal is a testament to Tilray's global commitment to increasing safe and regulated access to medical cannabis products for patients in need."
Tilray Medical offers a diverse portfolio of EU-GMP-certified medicinal marijuana products, and its operations extend to over 20 countries.
In 2001, Portugal became the first nation in the world to decriminalize the possession and use of all drugs, including cannabis in an effort to combat drug abuse and reduce drug-related crime. Then in 2018 it approved medical marijuana legalization and regulated it the following year. Even though medical marijuana is legal it can only prescribed to patients suffering from seven specific conditions for which other traditional treatments failed. To make things more complicated the only two medical marijuana products that were sold in Portugal until now are Tilray's 18% THC cannabis flower and Tilray Oral Solution THC 5 CBD 20.
大麻巨头蒂尔雷品牌公司（纳斯达克股票代码：TLRY）周三宣布，其新的医用大麻提取物已在葡萄牙获得第二次批准。获得此批准的医用大麻提取物是Tilray口服溶液THC10：CBD10。
这一里程碑是继Tilray Medical的全花四氢大麻酚18获得成功批准以及葡萄牙今年早些时候批准第一种大麻提取物之后发生的。今年，Tilray一直在广泛拓展其欧洲业务。该公司本周证实，其德国大麻种植设施Aphria RX GmbH已获得根据德国新的大麻法案MedCang颁发的第一份新的大麻种植许可证。
Tilray Brands, Inc.首席战略官兼国际负责人丹尼斯·法尔蒂舍克说：“我们很自豪我们的Tilray Solucao口服THC10：CBD10产品获得批准，并扩大了我们为葡萄牙患者提供的医用大麻产品，这是朝着满足患者护理的关键需求以及为患有特定疾病的人提供高质量的大麻产品和治疗选择方面迈出的重要一步。这种口服大麻解决方案在葡萄牙获得批准，证明了Tilray的全球承诺，即增加有需要的患者获得医用大麻产品的安全和受监管的机会。”
Tilray Medical提供多元化的欧盟GMP认证药用大麻产品组合，其业务扩展到20多个国家。
2001年，葡萄牙成为世界上第一个将拥有和使用包括大麻在内的所有毒品合法化的国家，以打击药物滥用和减少与毒品有关的犯罪。然后在2018年，它批准了医用大麻合法化，并于次年对其进行了监管。尽管医用大麻是合法的，但它只能向患有其他传统治疗失败的七种特定疾病的患者开处方。更复杂的是，到目前为止，在葡萄牙销售的仅有的两种医用大麻产品是蒂尔雷的18％四氢大麻酚大麻花和Tilray口服溶液THC 5 CBD 20。
